| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(13)60594-2 |
| P698 | PubMed publication ID | 23769296 |
| P50 | author | Kim A. Papp | Q54269356 |
| Arthur Kavanaugh | Q93106996 | ||
| Winfried B. Graninger | Q38639365 | ||
| Iain McInnes | Q41687181 | ||
| Luis Puig | Q42669207 | ||
| P2093 | author name string | Shu Li | |
| Yuhua Wang | |||
| Proton Rahman | |||
| Alan M Mendelsohn | |||
| Alice B Gottlieb | |||
| Carrie Brodmerkel | |||
| Christopher Ritchlin | |||
| Mittie K Doyle | |||
| PSUMMIT 1 Study Group | |||
| P2860 | cites work | IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells | Q46043893 |
| Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial | Q46585904 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts | Q48920916 | ||
| Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. | Q50882370 | ||
| Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. | Q51821980 | ||
| An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. | Q54580427 | ||
| Measurement of patient outcome in arthritis | Q56879288 | ||
| Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations | Q57169471 | ||
| Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis | Q58466080 | ||
| Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis | Q58992083 | ||
| Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death | Q60700017 | ||
| Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e | Q63101754 | ||
| Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis | Q82964583 | ||
| A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci | Q21145042 | ||
| The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 | ||
| Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis | Q28270369 | ||
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) | Q28280453 | ||
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) | Q28280465 | ||
| Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation | Q29614224 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Severe Psoriasis – Oral Therapy with a New Retinoid | Q34690752 | ||
| Prevalence of joint disease in patients with psoriasis: implications for therapy | Q35157479 | ||
| Assessment of enthesitis in ankylosing spondylitis | Q35552370 | ||
| Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial | Q35555905 | ||
| Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features | Q36245883 | ||
| A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis | Q37908827 | ||
| European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies | Q37939700 | ||
| Investigation of association of the IL12B and IL23R genes with psoriatic arthritis | Q41134319 | ||
| Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. | Q42495512 | ||
| IL-12p35 promotes antibody-induced joint inflammation by activating NKT cells and suppressing TGF-beta | Q43731761 | ||
| P433 | issue | 9894 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| multicenter clinical trial | Q6934595 | ||
| psoriatic arthritis | Q511097 | ||
| placebo | Q269829 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 780-789 | |
| P577 | publication date | 2013-06-13 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. | |
| P478 | volume | 382 |
| Q60061979 | 10 years of therapeutic advances in the rheumatic diseases |
| Q90664422 | A Review for Physician Assistants and Nurse Practitioners on the Considerations for Diagnosing and Treating Psoriatic Arthritis |
| Q38840271 | A Review of Psoriasis, Therapies, and Suicide. |
| Q44268181 | A novel biological target for the treatment of psoriatic arthritis |
| Q36557095 | A novel human truncated IL12rβ1-Fc fusion protein ameliorates experimental autoimmune encephalomyelitis via specific binding of p40 to inhibit Th1 and Th17 cell differentiation |
| Q40372208 | A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate |
| Q38236514 | A review of disease activity measures for psoriatic arthritis: what is the best approach? |
| Q38749257 | A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases |
| Q38858335 | A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis |
| Q56891106 | Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives |
| Q99547421 | Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review |
| Q35586614 | Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation |
| Q91737183 | Advances in nanomedicine for the treatment of ankylosing spondylitis |
| Q38227264 | Advances in the management of psoriatic arthritis |
| Q27001017 | Advances in the treatment of polyarticular juvenile idiopathic arthritis |
| Q38193099 | Advances in treating psoriasis |
| Q47734526 | Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions |
| Q99238557 | An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis |
| Q91015238 | Ankylosing spondylitis: etiology, pathogenesis, and treatments |
| Q47727612 | Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions |
| Q38202205 | Apremilast for the treatment of psoriatic arthritis |
| Q38616811 | Apremilast for the treatment of psoriatic arthritis |
| Q55109332 | Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review. |
| Q60821883 | Association between IL23R and ERAP1 polymorphisms and sacroiliac or spinal MRI inflammation in spondyloarthritis: DESIR cohort data. |
| Q50034719 | Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis. |
| Q38845301 | Autoinflammation and HLA-B27: Beyond Antigen Presentation |
| Q55117680 | Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. |
| Q93106999 | Bedside to bench: defining the immunopathogenesis of psoriatic arthritis |
| Q27702597 | Benzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH 17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORγ |
| Q92410206 | Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia |
| Q38766379 | Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis |
| Q38155648 | Biological therapies for psoriasis |
| Q38217223 | Biological therapies for spondyloarthritis |
| Q38866152 | Biologics in Pediatric Rheumatology: Quo Vadis? |
| Q38488577 | Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis |
| Q36008355 | CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses |
| Q92422137 | Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review |
| Q38344194 | Certolizumab pegol for the treatment of psoriatic arthritis |
| Q64231010 | Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review |
| Q89074054 | Clinical management of psoriatic arthritis |
| Q90593383 | Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic |
| Q90028565 | Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis |
| Q40427746 | Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis |
| Q38648826 | Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison |
| Q26764820 | Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-Analysis |
| Q47236145 | Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. |
| Q38553845 | Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis |
| Q88495316 | Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective |
| Q51289760 | Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system. |
| Q64250024 | Current advances in the treatment of giant cell arteritis: the role of biologics |
| Q38912297 | Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis). |
| Q49722360 | Cutaneous Manifestations of Reactions to Biologics |
| Q38180799 | Cytokine networking of innate immunity cells: a potential target of therapy. |
| Q38459083 | Cytokines: Names and Numbers You Should Care About |
| Q38165235 | Diagnosing and treating psoriatic arthritis: an update |
| Q38998373 | Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis |
| Q44477550 | Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel. |
| Q34727681 | Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era |
| Q38759376 | Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options |
| Q34380190 | Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy |
| Q91934535 | Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases |
| Q48093013 | Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). |
| Q47230622 | Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study |
| Q91860943 | Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis |
| Q90630025 | Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials |
| Q89865617 | Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis |
| Q49824739 | Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis |
| Q38365042 | Efficacy and safety of emerging immunotherapies in psoriasis. |
| Q89074034 | Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study |
| Q40164172 | Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial |
| Q33659249 | Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas |
| Q40705952 | Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). |
| Q90465560 | Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis |
| Q38202538 | Efficacy of tocilizumab in a patient with refractory psoriatic arthritis |
| Q90355990 | Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2 |
| Q38710642 | Emerging drugs for psoriatic arthritis |
| Q38313266 | Emerging drugs for the treatment of axial and peripheral spondyloarthritis |
| Q90232146 | Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management |
| Q47329414 | Enthesitis: from pathophysiology to treatment |
| Q38661777 | European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update |
| Q90147852 | Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression |
| Q61812079 | Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments |
| Q38838470 | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. |
| Q99632335 | Extrapolating Pharmacodynamic Effects from Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients with Moderate to Severe Plaque Psoriasis |
| Q48115736 | First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. |
| Q98210385 | Fourteen small molecule and biological agents for psoriatic arthritis: A network meta-analysis of randomized controlled trials |
| Q63352496 | Genome wide analysis for mouth ulcers identifies associations at immune regulatory loci |
| Q39446770 | Genomics and epigenomics in rheumatic diseases: what do they provide in terms of diagnosis and disease management? |
| Q38691418 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis |
| Q38539811 | Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies |
| Q38120199 | How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy |
| Q38539817 | IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. |
| Q61651896 | IL-17 in the immunopathogenesis of spondyloarthritis |
| Q90345257 | IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology |
| Q38255855 | IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application |
| Q39032463 | IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy |
| Q38421287 | IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear. |
| Q38733759 | Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. |
| Q26800688 | Identifying a novel locus for psoriatic arthritis |
| Q45756098 | Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. |
| Q36367126 | Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome |
| Q57067878 | Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease |
| Q40284292 | Interleukin-12 and Interleukin-23 Blockade in Leukocyte Adhesion Deficiency Type 1. |
| Q89762380 | Interleukin-17A and Keratinocytes in Psoriasis |
| Q38206551 | Investigational drugs for treating psoriatic arthritis |
| Q42094104 | Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis |
| Q51648725 | Juvenile Spondyloarthropathies. |
| Q38199165 | Lessons from helminth infections: ES-62 highlights new interventional approaches in rheumatoid arthritis. |
| Q41454181 | Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. |
| Q26783506 | Making the next steps in psoriatic arthritis management: current status and future directions |
| Q35773115 | Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease |
| Q64967615 | Management of Psoriasis and Psoriatic Arthritis in a Multidisciplinary Rheumatology/Dermatology Clinic. |
| Q39004045 | Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations |
| Q38145008 | Mechanistic insights from animal models of psoriasis and psoriatic arthritis. |
| Q92856727 | Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis |
| Q88205381 | Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study |
| Q37713522 | Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis |
| Q92464630 | Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis |
| Q38799979 | New evidence on the management of spondyloarthritis. |
| Q99240843 | New insights into IL-17/IL-23 signaling in ankylosing spondylitis (Review) |
| Q28069592 | New targets in psoriatic arthritis |
| Q38266252 | New treatments for inflammatory rheumatic disease |
| Q47141159 | Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab. |
| Q54977688 | Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline? |
| Q38634276 | Novel approaches to biological therapy for psoriatic arthritis |
| Q46753645 | Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients |
| Q28072557 | Optimal management of dactylitis in patients with psoriatic arthritis |
| Q90046667 | Pathogenesis of spondylarthritis : Relevance for treatment |
| Q35860158 | Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients |
| Q35658540 | Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment |
| Q33800651 | Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab |
| Q38692257 | Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab |
| Q37460263 | Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis |
| Q38527552 | Pharmacological therapy of spondyloarthritis |
| Q38667430 | Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis |
| Q26777084 | Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies |
| Q26825174 | Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease |
| Q37301177 | Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis. |
| Q50553314 | Psoriasis vs. psoriatic arthritis : Similarities and differences in the pathophysiology |
| Q90470107 | Psoriatic arthritis |
| Q51656945 | Psoriatic arthritis. |
| Q38542095 | Psoriatic arthritis: latest treatments and their place in therapy |
| Q38194559 | Psoriatic arthritis: recent progress in pathophysiology and drug development. |
| Q38985830 | Psoriatic arthritis: state of the art review |
| Q38658837 | Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist. |
| Q57821877 | Recent advances in ankylosing spondylitis: understanding the disease and management |
| Q53733372 | Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis. |
| Q38679357 | Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement |
| Q30399745 | Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders |
| Q37541327 | Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment |
| Q26991709 | Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond |
| Q38555291 | Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis. |
| Q97530140 | Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis |
| Q38357554 | Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges |
| Q33809045 | Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics |
| Q52608145 | Role of Methotrexate in the Management of Psoriatic Arthritis. |
| Q50099588 | Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints |
| Q38161956 | Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update |
| Q40069149 | Secondary syphilis infection under treatment with ustekinumab. |
| Q26738523 | Secukinumab for rheumatology: development and its potential place in therapy |
| Q38989105 | Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q35963238 | Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. |
| Q64229191 | Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials |
| Q47114261 | Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence |
| Q38693137 | T Helper 17 Cells in Primary Sjögren's Syndrome |
| Q38816316 | T cells and IL-17 in lupus nephritis. |
| Q87807672 | Tailored approach to early psoriatic arthritis patients: clinical and ultrasonographic predictors for structural joint damage |
| Q26764867 | Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies |
| Q90374956 | Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances |
| Q38969036 | Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis |
| Q47140713 | Targeting IL-17 in psoriatic arthritis |
| Q93246335 | Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis |
| Q38664951 | Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis |
| Q37456949 | Th17-associated cytokines as a therapeutic target for steroid-insensitive asthma |
| Q38815070 | The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis |
| Q30235002 | The Changing Face of Clinical Trials in Psoriatic Arthritis |
| Q30383929 | The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence. |
| Q38879975 | The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy? |
| Q90262614 | The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis |
| Q90430023 | The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling |
| Q58567074 | The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future |
| Q35308947 | The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications |
| Q38191200 | The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment |
| Q52810424 | The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. |
| Q98460557 | The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis |
| Q38976762 | The role of IL 23 in the treatment of psoriasis |
| Q39328684 | The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade |
| Q39293096 | The role of IL-17 in the treatment of psoriatic arthritis |
| Q91664106 | The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies |
| Q38820480 | The safety of ustekinumab for the treatment of psoriatic arthritis |
| Q39015080 | Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders. |
| Q50862504 | Therapy: Ustekinumab therapeutic effects--more than skin deep. |
| Q36475599 | Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors |
| Q54194408 | Transforming growth factor-β1 mediates psoriasis-like lesions via a Smad3-dependent mechanism in mice. |
| Q58639485 | Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT) |
| Q33659004 | Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor |
| Q39003610 | Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations. |
| Q51342040 | Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. |
| Q96953884 | Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors |
| Q38685543 | Tumor necrosis factor inhibitors in psoriatic arthritis. |
| Q38264660 | Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity |
| Q46941311 | Unique topics and issues in rheumatology and clinical immunology |
| Q37258726 | Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting |
| Q34377347 | Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting |
| Q34553755 | Use of biologic agents in combination with other therapies for the treatment of psoriasis |
| Q38167615 | Using genetic findings in autism for the development of new pharmaceutical compounds. |
| Q58008027 | Ustekinumab (Stelara®1)2 |
| Q38189853 | Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. |
| Q41813468 | Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis |
| Q50906229 | Ustekinumab for psoriatic arthritis: close to the PSUMMIT? |
| Q50237402 | Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. |
| Q26771890 | Ustekinumab for the treatment of Crohn's disease: can it find its niche? |
| Q38438153 | Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). |
| Q38177336 | Ustekinumab for the treatment of psoriatic arthritis |
| Q34154247 | Ustekinumab for the treatment of psoriatic arthritis: an update |
| Q91828617 | Ustekinumab in psoriatic arthritis and related phenotypes |
| Q36942960 | Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis |
| Q42956548 | Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential |
| Q28067631 | Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy |
| Q30760660 | Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla |
| Q86162712 | Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis |
| Q38219591 | Ustekinumab: a review of its use in psoriatic arthritis |
| Q38177321 | Ustekinumab: moving the target from psoriasis to Crohn's disease |
| Q41591385 | WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). |
| Q92737085 | What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials |
| Q26778261 | What makes psoriatic and rheumatoid arthritis so different? |
| Q57293183 | Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? |
| Q86704222 | [Genetic risk factors for vasculitis] |
| Q54374459 | [New drugs in rheumatology]. |
| Q88420740 | [Psoriatic arthritis : Current therapeutic standards] |
| Q52927228 | [Psoriatic arthritis : Overview of drug therapy options and administration characteristics]. |
| Q53760739 | [Psoriatic arthritis : Overview of drug therapy options and administration characteristics]. |
| Q85882358 | [Therapy of psoriatic arthritis] |
| Q90442686 | [Treatment of psoriatic arthritis : Are there differential indications?] |
Search more.